Published in Int J Oncol on June 10, 2014
Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. Ann Transl Med (2015) 1.42
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. J Transl Med (2015) 0.81
Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma. Biologics (2016) 0.77
Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. Pigment Cell Melanoma Res (2016) 0.77
Proteasome inhibitors against amelanotic melanoma. Cell Biol Toxicol (2017) 0.76
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. Cancers (Basel) (2015) 0.75
NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma. Oncol Rep (2017) 0.75
Curcumin analog DM-1 in monotherapy or combinatory treatment with dacarbazine as a strategy to inhibit in vivo melanoma progression. PLoS One (2015) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell (2006) 10.19
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92
The expanding role of mitochondria in apoptosis. Genes Dev (2001) 9.91
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res (2008) 9.65
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell (2006) 8.59
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
The Akt-mTOR tango and its relevance to cancer. Cancer Cell (2005) 5.34
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A (2007) 4.92
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci (2011) 3.89
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 3.80
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
IAP-targeted therapies for cancer. Oncogene (2008) 3.09
Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol (2013) 2.92
Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res (2010) 2.90
A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer (2008) 2.63
Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol (2001) 2.58
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 2.53
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 2.42
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res (2011) 2.42
Life and death by death receptors. FASEB J (2009) 2.39
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res (2005) 2.37
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res (2005) 2.27
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther (2012) 2.21
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2004) 2.17
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest (2008) 2.17
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer (2010) 2.04
Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res (2008) 1.99
Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov (2012) 1.97
Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev (2005) 1.93
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One (2011) 1.89
Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res (1999) 1.88
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res (2006) 1.85
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res (2012) 1.74
Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes Cancer (2013) 1.73
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res (2011) 1.73
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol (2008) 1.71
MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res (2010) 1.68
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res (2011) 1.56
Melanoma: new insights and new therapies. J Invest Dermatol (2012) 1.54
Understanding melanoma signaling networks as the basis for molecular targeted therapy. J Invest Dermatol (2010) 1.53
Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res (2012) 1.52
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol (2007) 1.49
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol (2013) 1.46
Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res (2009) 1.44
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep (2013) 1.43
Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res (2006) 1.41
Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res (2012) 1.41
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol (2011) 1.40
B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis. Oncogene (2006) 1.39
Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun (1993) 1.38
Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol (2011) 1.37
The clinical trail of TRAIL. Eur J Cancer (2006) 1.35
HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res (2008) 1.33
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res (2009) 1.32
Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer (2009) 1.30
RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway. PLoS One (2009) 1.28
Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin Cancer Res (2011) 1.27
On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol (2007) 1.27
Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia (2011) 1.26
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis (2010) 1.25
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ (2012) 1.24
Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ (2007) 1.24
Death receptors as targets in cancer. Br J Pharmacol (2013) 1.24
c-FLIP, a master anti-apoptotic regulator. Exp Oncol (2012) 1.24
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med (2005) 1.22
Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res (2009) 1.18